COMPASS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 USD | +3.03% |
|
+17.24% | +8.97% |
| 04-25 | Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment | MT |
| 04-25 | Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment | DJ |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 309 | 633.5 | 198.8 | 233.9 | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 233.9 | 233.9 | 233.9 |
| P/E ratio | -2.42 x | -13.6 x | -4.73 x | -3.51 x | -3.38 x | -10.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 20.9 x | 2.32 x |
| EV / Revenue | - | - | - | - | 20.9 x | 2.32 x |
| EV / EBITDA | -3.8 x | -15.5 x | -4 x | -3.46 x | -3.09 x | -3.25 x |
| EV / FCF | -14,336,714 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | - | - |
| Reference price 2 | 3.170 | 5.030 | 1.560 | 1.700 | 1.700 | 1.700 |
| Announcement Date | 18/03/22 | 15/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 11.19 | 100.9 |
| EBITDA 1 | - | -81.32 | -40.87 | -49.66 | -67.56 | -75.61 | -72.06 |
| EBIT 1 | - | -81.88 | -41.66 | -50.36 | -68.3 | -81.32 | -32.83 |
| Operating Margin | - | - | - | - | - | -726.84% | -32.54% |
| Earnings before Tax (EBT) 1 | -29.47 | -82.18 | -39.22 | -42.49 | -64.88 | -78.54 | -29.99 |
| Net income 1 | -29.5 | -82.18 | -39.22 | -42.49 | -66.34 | -79.35 | -27.21 |
| Net margin | - | - | - | - | - | -709.23% | -26.96% |
| EPS 2 | - | -1.310 | -0.3700 | -0.3300 | -0.4843 | -0.5029 | -0.1614 |
| Free Cash Flow | - | -21.55 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 05/03/21 | 18/03/22 | 15/03/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | -12.88 | -7.017 | -8.767 | -12.4 | -12.69 | -9.517 | -13.16 | -11.76 | -15.23 | -15.7 | -16.24 | -17.58 | -18.03 | -17.03 |
| EBIT 1 | -5.854 | -13 | -7.182 | -8.987 | -12.6 | -12.89 | -9.711 | -13.34 | -11.93 | -15.39 | -15.51 | -16.5 | -17.28 | -18.19 | -17.2 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -5.975 | -12.99 | -7.162 | -8.494 | -11.98 | -11.59 | -7.837 | -11.28 | -9.964 | -13.42 | -14.51 | -15.52 | -16.66 | -17.62 | -17.2 |
| Net income 1 | -5.975 | -12.98 | -7.162 | -8.494 | -11.98 | -11.59 | -7.837 | -11.28 | -9.964 | -13.42 | -14.78 | -15.98 | -17.07 | -18.02 | -17.2 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1000 | -0.0500 | -0.0700 | -0.0800 | -0.1200 | -0.1000 | -0.0600 | -0.0900 | -0.0800 | -0.1100 | -0.1129 | -0.1200 | -0.1243 | -0.1229 | -0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/21 | 18/03/22 | 09/05/22 | 01/08/22 | 09/11/22 | 15/03/23 | 04/05/23 | 03/08/23 | 09/11/23 | 21/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -21.6 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 1.89 | 0.21 | - | 0.03 | 0.03 | 0.03 |
| Capex / Sales | - | - | - | - | - | 0.27% | 0.03% |
| Announcement Date | 05/03/21 | 18/03/22 | 15/03/23 | 21/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.7
USD
Average target price
9.167
USD
Spread / Average Target
+439.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.97% | 234M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- CMPX Stock
- Financials Compass Therapeutics, Inc.
